Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease

NCT07488377 | Not Yet Recruiting

• 1 other identifier: 2026-05-223
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to evaluate the validity and reliability of the Turkish version of the Cognitive Self-Efficacy Questionnaire in individuals with Parkinson's disease.

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire (CSEQ)

  Assessment of the psychometric properties of the Turkish version of the CSEQ in individuals with Parkinson's disease, including internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient), and construct validity through factor and correlation analyses.

  Baseline and 14-21 days for test-retest assessment

Secondary Outcomes (2)

• Self-Efficacy for Managing Chronic Disease (6-Item Scale)

  Baseline

• Montreal Cognitive Assessment (MoCA-TR)

  Baseline

Interventions

Cognitive Self-Efficacy Questionnaire (Turkish Version) OTHER

Participants will complete the Turkish version of the Cognitive Self-Efficacy Questionnaire to assess cognitive self-efficacy. The questionnaire will be administered for the evaluation of its validity and reliability in individuals with Parkinson's disease.

Eligibility Criteria

• Age: 40 Years - 85 Years
• Gender Eligibility Details: Both male and female participants will be included in the study. No gender-based restrictions will be applied.
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of individuals diagnosed with Parkinson's disease who are attending the Movement Disorders Outpatient Clinic at the Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital. Eligible participants will be between 40 and 85 years of age, have sufficient cognitive function to communicate (MMSE ≥ 24), and provide informed consent. A total of 100 patients will be recruited for the study.

You may qualify if:

• Clinically diagnosed with Parkinson's disease
• Aged between 40 and 85 years
• MMSE score ≥ 24 (adequate cognitive level for communication)
• Voluntary participation with informed consent
• Patients attending the Movement Disorders Outpatient Clinic, Department of Neurology

You may not qualify if:

• Presence of psychiatric disorders (major depression, psychotic disorders)
• Diagnosis of advanced dementia
• Severe visual or hearing impairment that may interfere with assessments
• Inability to cooperate with the physiotherapist or complete the assessments

Sponsors & Collaborators

• Acibadem University: lead

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 2 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2026
• First Posted: March 23, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): April 1, 2027
• Last Updated: March 23, 2026

Record last verified: 2026-03